CompletedNCT05439629
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
PHASE3 · 488 planned enrolment
- Countries listed
- 1
- Registry update
- December 8, 2025
immortal.lifeTrial registrations containing the exact intervention label lucentis.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 488 planned enrolment
PHASE2 · 64 planned enrolment
PHASE2 · 1 planned enrolment
PHASE2 · 449 planned enrolment
PHASE2 · PHASE3 · 433 planned enrolment
PHASE2 · 76 planned enrolment
Phase not reported · 5,500 planned enrolment
PHASE1 · 48 planned enrolment
PHASE4 · 20 planned enrolment
PHASE2 · 0 planned enrolment
PHASE1 · 50 planned enrolment
Phase not reported · 30 planned enrolment